Our novel antibody engineering platform, ATTOBODY™, consists of a proprietary design framework and an efficient discovery process that yields optimized bi-paratopic nanobodies consisting of two variable domains of single heavy chain (VHH) antibodies.
Bi-paratropic binding and binder optimization drive high affinity and specificity
Tunable half-life allows for flexibility in optimizing PK/PD to achieve ideal therapeutic index
Expanded epitope diversity and a greater number of druggable leads
Simpler manufacturing shortens development times
The ATTOBODY platform enables the development of highly specific and sensitive detection reagents for challenging targets that lack quality off-the-shelf antibodies. Combining ATTOBODY reagents with the NULISA assay platform will enable a new generation of precision diagnostics for the early detection of cancer and other common diseases.
A recent advertorial in Nature on our ATTOBODY technology.
FOR RESEARCH USE ONLY. Not for use in diagnostic procedures.
Looking for more information? Contact us today and a representative will reach out to you soon.